Impact of radiotherapy pattern on the prognosis of stage IV lung adenocarcinomas harboring EGFR mutations

被引：0
|
作者：
Zhang, Y. [1 ]
Wang, W. [1 ]
Li, J. [1 ]
Li, Z. [1 ]
Li, Y. [2 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong Univ, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1839
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1234P
引用
收藏
页码：S976 / S976
页数：1
相关论文
共 50 条
  • [41] Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas
    Schilsky, Juliana B.
    Ni, Ai
    Ahn, Linda
    Datta, Sutirtha
    Travis, William D.
    Kris, Mark G.
    Chaft, Jamie E.
    Rekhtman, Natasha
    Hellmann, Matthew D.
    LUNG CANCER, 2017, 108 : 205 - 211
  • [42] The Impact of TP53 Overexpression on EMT and the Prognosis in Lung Adenocarcinoma Harboring Driver Mutations
    Nishikawa, Shigeto
    Menju, Toshi
    Soawa, Terumasa
    Takahashi, Koji
    Miyata, Ryo
    Cho, Hiroyuki
    Neri, Shinya
    Nakanishi, Takao
    Hamaji, Masatsugu
    Motoyama, Hideki
    Hijiya, Kyoko
    Aoyama, Akihiro
    Sato, Toshihiko
    Chen, Fengshi
    Sonobe, Makoto
    Date, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S529 - S530
  • [43] A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, M.
    Hua, Y.
    Su, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1735 - S1735
  • [44] Radiogenomic evaluation of lung cancer Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?
    Halpenny, Darragh F.
    Plodkowski, Andrew
    Riely, Gregory
    Zheng, Junting
    Litvak, Anya
    Moscowitz, Chaya
    Ginsberg, Michelle S.
    CLINICAL IMAGING, 2017, 42 : 147 - 151
  • [45] Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
    Paik, Paul K.
    Johnson, Melissa L.
    D'Angelo, Sandra P.
    Sima, Camelia S.
    Ang, Daphne
    Dogan, Snjezana
    Miller, Vincent A.
    Ladanyi, Marc
    Kris, Mark G.
    Riely, Gregory J.
    CANCER, 2012, 118 (23) : 5840 - 5847
  • [46] Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, Y.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Performance characteristics for a diagnostic molecular test for EGFR gene mutations, KRAS mutations, and EGFR amplification in lung adenocarcinomas
    Caglar, D
    Dacic, S
    Mantha, GS
    Hunt, JL
    LABORATORY INVESTIGATION, 2006, 86 : 304A - 304A
  • [48] Performance characteristics for a diagnostic molecular test for EGFR gene mutations, KRAS mutations, and EGFR amplification in lung adenocarcinomas
    Caglar, D
    Dacic, S
    Mantha, GS
    Hunt, JL
    MODERN PATHOLOGY, 2006, 19 : 304A - 304A
  • [49] Tumor immunoediting in a lung cancer mouse model harboring EGFR mutations
    Nishii, Kazuya
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Makimoto, Go
    Watanabe, Hiromi
    Kano, Hirohisa
    Hara, Naofumi
    Udono, Heiichiro
    Kiura, Katsuyuki
    CANCER RESEARCH, 2019, 79 (13)
  • [50] EGFR Mutations and Targeted Treatment Reverse the Bad Prognosis of Stage IV NSCLC Associated to Liver Metastasis
    Castanon, Eduardo
    Rolfo, Christian
    Vinal, David
    Lopez, Ines
    Fusco, Juan P.
    Martin, Patricia
    Zubiri, Leire
    Echeveste, Jose I.
    Gil-Bazo, Ignacio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S410 - S410
12345